Osteologix, Inc. (OLGX.OB) Receives Positive Patent Decision for Key Osteoporosis Drug in Japan
Osteologix, Inc., a specialty biopharmaceutical company committed to improving the health of those afflicted with musculoskeletal diseases, yesterday announced that the company has been informed that a positive decision was made in Japan to grant a patent for a key osteoporosis drug. The Japan Patent Office (JPO) has issued Osteologix, Inc. a decision to grant a patent for application number 2006-504379: “Treating Cartilage/Bone Conditions with Water-Soluble Strontium Salts.” The patent is for NB S101 (strontium malonate), the company’s lead osteoporosis drug candidate. Osteologix expects that the patent will be issued by the end of 2009 with a 20-year term that…